Welcome to our dedicated page for Clene SEC filings (Ticker: CLNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Clene’s nanocrystal breakthrough is exciting—decoding its SEC paperwork is not. Each 10-K details millions in R&D for CNM-Au8, every 8-K flags trial readouts, and Form 4 insider trades hint at executive confidence. Finding those nuggets across hundreds of pages is the real challenge.
Stock Titan solves that problem. Our AI-powered summaries break down Clene SEC filings explained simply, highlighting cash runway, NIH grant inflows, and milestone payments in seconds. Whether you search "How to read Clene’s 10-K annual report" or "Where can I find Clene’s quarterly earnings report 10-Q filing?", you land on real-time documents the moment they post to EDGAR—already analyzed.
Here’s what you’ll uncover faster:
- 10-Q & 10-K: R&D spend, liquidity outlook, and nanocrystal manufacturing costs—Clene annual report 10-K simplified.
- Form 4: Clene insider trading Form 4 transactions and executive stock moves, delivered as "Clene Form 4 insider transactions real-time" alerts.
- 8-K: Clinical data drops and financing updates—Clene 8-K material events explained.
- DEF 14A proxy: Clene proxy statement executive compensation and milestone-based pay structures.
Stop skimming PDFs and start asking bigger questions: "understanding Clene SEC documents with AI" or "Clene earnings report filing analysis." Our platform turns complex biotech disclosure into clear, actionable insight so you can decide—quickly—whether Clene’s next catalyst merits attention.
Clene Inc. reported insider selling of common stock by a 10% owner in December 2025. The Form 4 shows a series of open-market sales coded "S" from
After these sales, the reporting person beneficially owned 393,150 shares of Clene common stock, held indirectly via Symbiosis II, LLC as of
Clene Inc. (CLNN) disclosed a director stock option grant. On 11/13/2025, the director received an option for 1,893 shares of common stock at an exercise price of $7.30 per share under the Amended 2020 Stock Plan. The option vests immediately upon grant and expires on 11/12/2035.
Following the transaction, the filing shows 1,893 derivative securities beneficially owned, held in direct ownership.
Clene Inc. (CLNN)November 13, 2025, the director received a stock option covering 2,438 shares of common stock at an exercise price of $7.30 per share under the Clene Inc. Amended 2020 Stock Plan. The option vests immediately upon grant and carries an expiration date of November 12, 2035.
The filing classifies the transaction as an acquisition of derivative securities and lists direct ownership following the grant.
Clene Inc. (CLNN) reported an insider equity award. A director filed a Form 4 disclosing a stock option grant for 2,887 shares of common stock at an exercise price of $7.30 per share on November 13, 2025. The options vest immediately upon grant under the Clene Inc. Amended 2020 Stock Plan and carry an expiration date of November 12, 2035. Following the transaction, the filing shows 2,887 derivative securities beneficially owned with direct ownership.
Clene Inc. (CLNN)2,816 shares of Clene common stock under the company’s Amended 2020 Stock Plan. The option has an exercise price of $7.30 per share and vests immediately, meaning the director can exercise it right away, subject to plan terms. The option is scheduled to expire on November 12, 2035 if not exercised.
Clene Inc. (CLNN) reported a routine insider transaction: a director received a stock option grant for 1,893 shares on 11/13/2025 under the Amended 2020 Stock Plan at an exercise price of $7.30 per share.
The options vest immediately upon grant and expire on 11/12/2035. Ownership of the derivative securities is reported as direct.
Clene Inc. furnished an 8-K announcing third quarter 2025 financial results and recent operating highlights for the quarter ended September 30, 2025. The details are provided in a press release furnished as Exhibit 99.1 and incorporated by reference. The Item 2.02 information is furnished, not filed, and is not subject to Section 18 liabilities. The filing also lists the company’s Nasdaq-listed common stock (CLNN) and warrants (CLNNW).
Clene Inc. reported Q3 2025 results highlighting limited revenue and continued losses. Total revenue was $15 thousand (product $0, royalty $15 thousand). Loss from operations was $5.6 million, and net loss was $8.8 million (basic and diluted EPS $(0.85)).
Cash and cash equivalents were $7.9 million at September 30, 2025, down from $12.2 million at year-end. Net cash used in operating activities for the nine months was $13.7 million. The company reported a stockholders’ deficit of $12.4 million. Management stated that conditions “raise substantial doubt” about the ability to continue as a going concern, including a covenant to maintain at least $2.0 million of unrestricted cash under the 2024 senior secured convertible notes.
To support liquidity, Clene raised $3.3 million via its equity distribution agreement during Q3 and $1.5 million from new senior secured convertible notes, and subsequently generated $1.2 million more from the equity distribution. Shares outstanding were 10,333,980 as of November 10, 2025. Grant funding reduced expenses by $2.3 million (R&D) and $0.1 million (G&A) in the quarter.
Clene Inc. (CLNN) expanded its at-the-market equity program. The company previously entered into an equity distribution agreement to offer and sell common stock with an aggregate offering price of up to $25,000,000 through Canaccord Genuity LLC.
As of October 17, 2025, Clene reported prior sales of approximately $6,119,859 under this program and filed a prospectus supplement covering an additional $18,880,000 of common stock. A legal opinion from Holland & Knight LLP regarding the validity of the shares was filed as Exhibit 5.1.
Clene Inc. may offer and sell shares of common stock with a maximum aggregate gross sales price of up to $18,880,000 from time to time through Canaccord Genuity under its at‑the‑market program, as updated by Prospectus Supplement No. 3.
This amount excludes $6,119,859 of shares sold under prior supplements to date. Clene will receive the proceeds from any sales, and Canaccord may receive a commission of up to 3.0% of the gross sales price per share. The company notes it is no longer subject to the General Instruction I.B.6 sales limitations for its S‑3. On October 15, 2025, Nasdaq reported last sale prices of $8.89 for CLNN and $0.0102 for CLNNW.
FAQ
What is the current stock price of Clene (CLNN)?
What is the market cap of Clene (CLNN)?
